343 related articles for article (PubMed ID: 27684274)
1. Utility of Macrophage-activated Marker CD163 for Diagnosis and Prognosis in Pulmonary Tuberculosis.
Suzuki Y; Shirai M; Asada K; Miwa S; Karayama M; Nakamura Y; Inui N; Shirai T; Hayakawa H; Baba S; Suda T
Ann Am Thorac Soc; 2017 Jan; 14(1):57-64. PubMed ID: 27684274
[TBL] [Abstract][Full Text] [Related]
2. Differential expression and predictive value of monocyte scavenger receptor CD163 in populations with different tuberculosis infection statuses.
Liu Q; Ou Q; Chen H; Gao Y; Liu Y; Xu Y; Ruan Q; Zhang W; Shao L
BMC Infect Dis; 2019 Nov; 19(1):1006. PubMed ID: 31779590
[TBL] [Abstract][Full Text] [Related]
3. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.
Peng QL; Zhang YL; Shu XM; Yang HB; Zhang L; Chen F; Lu X; Wang GC
J Rheumatol; 2015 Jun; 42(6):979-87. PubMed ID: 25877505
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of soluble CD163 as a specific marker of macrophage/monocyte activity in sarcoidosis patients.
Tanimura H; Mizuno K; Okamoto H
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Jul; 32(2):99-105. PubMed ID: 26278688
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of soluble haemoglobin scavenger receptor CD163 serum levels for survival in verified tuberculosis patients.
Knudsen TB; Gustafson P; Kronborg G; Kristiansen TB; Moestrup SK; Nielsen JO; Gomes V; Aaby P; Lisse I; Møller HJ; Eugen-Olsen J
Clin Microbiol Infect; 2005 Sep; 11(9):730-5. PubMed ID: 16104988
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
Enomoto Y; Suzuki Y; Hozumi H; Mori K; Kono M; Karayama M; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suzuki D; Ogawa N; Nakashima R; Mimori T; Iwashita T; Suda T
Arthritis Res Ther; 2017 Jan; 19(1):9. PubMed ID: 28103926
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of the soluble haemoglobin scavenger receptor CD163 in MPO-ANCA-associated renal vasculitis.
Nagai M; Hirayama K; Ebihara I; Higuchi T; Shimohata H; Kobayashi M
Scand J Rheumatol; 2016 Oct; 45(5):397-403. PubMed ID: 27094919
[TBL] [Abstract][Full Text] [Related]
8. Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma.
Andersen MN; Abildgaard N; Maniecki MB; Møller HJ; Andersen NF
Eur J Haematol; 2014 Jul; 93(1):41-7. PubMed ID: 24612259
[TBL] [Abstract][Full Text] [Related]
9. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
[TBL] [Abstract][Full Text] [Related]
10. CD163 levels, pro- and anti-inflammatory cytokine secretion of monocytes in children with pulmonary tuberculosis.
Aktas Cetin E; Pur Ozyigit L; Gelmez YM; Cakir E; Gedik AH; Deniz G
Pediatr Pulmonol; 2017 May; 52(5):675-683. PubMed ID: 27685837
[TBL] [Abstract][Full Text] [Related]
11. Macrophage activation marker, soluble CD163, is an independent predictor of short-term mortality in patients with cirrhosis and bacterial infection.
Tornai T; Vitalis Z; Sipeki N; Dinya T; Tornai D; Antal-Szalmas P; Karanyi Z; Tornai I; Papp M
Liver Int; 2016 Nov; 36(11):1628-1638. PubMed ID: 27031405
[TBL] [Abstract][Full Text] [Related]
12. Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163.
Møller HJ; Moestrup SK; Weis N; Wejse C; Nielsen H; Pedersen SS; Attermann J; Nexø E; Kronborg G
Crit Care Med; 2006 Oct; 34(10):2561-6. PubMed ID: 16915112
[TBL] [Abstract][Full Text] [Related]
13. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
Kazankov K; Tordjman J; Møller HJ; Vilstrup H; Poitou C; Bedossa P; Bouillot JL; Clement K; Grønbaek H
J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of haptoglobin and soluble CD163 testing for the differential diagnosis of tuberculous and malignant pleural effusions.
Gao J; Song L; Li D; Peng L; Ding H
Medicine (Baltimore); 2019 Oct; 98(42):e17416. PubMed ID: 31626097
[TBL] [Abstract][Full Text] [Related]
15. Soluble CD163 in young sickle cell disease patients and their trait siblings: a biomarker for pulmonary hypertension and vaso-occlusive complications.
Tantawy AA; Adly AA; Ismail EA
Blood Coagul Fibrinolysis; 2012 Oct; 23(7):640-8. PubMed ID: 22885767
[TBL] [Abstract][Full Text] [Related]
16. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio.
Moreno JA; Dejouvencel T; Labreuche J; Smadja DM; Dussiot M; Martin-Ventura JL; Egido J; Gaussem P; Emmerich J; Michel JB; Blanco-Colio LM; Meilhac O
Arterioscler Thromb Vasc Biol; 2010 Jun; 30(6):1253-62. PubMed ID: 20299688
[TBL] [Abstract][Full Text] [Related]
17. Increased serum levels of macrophage activation marker sCD163 in Dengue patients.
S S SG; Pillai AB; Ramachandrappa VS; T K; Dhodapkar R; Kah J; Rajendiran S
J Clin Virol; 2017 Jan; 86():62-67. PubMed ID: 27960133
[TBL] [Abstract][Full Text] [Related]
18. Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs.
Greisen SR; Møller HJ; Stengaard-Pedersen K; Hetland ML; Hørslev-Petersen K; Junker P; Østergaard M; Hvid M; Deleuran B
Clin Exp Rheumatol; 2015; 33(4):498-502. PubMed ID: 25962601
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension.
Jasiewicz M; Kowal K; Kowal-Bielecka O; Knapp M; Skiepko R; Bodzenta-Lukaszyk A; Sobkowicz B; Musial WJ; Kaminski KA
Cytokine; 2014 Mar; 66(1):40-5. PubMed ID: 24548423
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.
Waidmann O; Köberle V; Bettinger D; Trojan J; Zeuzem S; Schultheiß M; Kronenberger B; Piiper A
J Hepatol; 2013 Oct; 59(4):769-79. PubMed ID: 23792028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
